- Home
- ALHC vs ACAD Comparison
ALHC vs ACAD Comparison
Compare ALHC & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALHC | ACAD |
|---|---|---|
| Founded | 2013 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.9B |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | ALHC | ACAD |
|---|---|---|
| Price | $20.45 | $21.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 22 |
| Target Price | $23.00 | ★ $30.55 |
| AVG Volume (30 Days) | ★ 3.2M | 1.7M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | 69.12 |
| EPS | N/A | ★ 2.30 |
| Revenue | ★ $3,948,719,000.00 | $726,437,000.00 |
| Revenue This Year | $33.69 | $18.90 |
| Revenue Next Year | $24.74 | $11.62 |
| P/E Ratio | $405.00 | ★ $9.81 |
| Revenue Growth | ★ 46.06 | 40.45 |
| 52 Week Low | $11.63 | $14.08 |
| 52 Week High | $23.87 | $28.35 |
Technical Indicators
Market Signals| Indicator | ALHC | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 59.76 | 46.16 |
| Support Level | $19.93 | $21.51 |
| Resistance Level | $20.71 | $22.03 |
| Average True Range (ATR) | 0.91 | 0.72 |
| MACD | 0.53 | 0.19 |
| Stochastic Oscillator | 63.71 | 51.38 |
Price Performance
Historical ComparisonAbout ALHC Alignment Healthcare Inc.
Alignment Healthcare Inc is a next-generation, consumer-centric platform that is revolutionizing the healthcare experience for seniors through Medicare Advantage plans. These plans are marketed and sold direct-to-consumer, allowing seniors to select the manner in which customers receive healthcare coverage and services on an annual basis. The company combines a technology platform and clinical model for more effective health outcomes.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.